TG Therapeutics, Inc. - Common Stock (TGTX)

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) ( Profile ) is determined working to change that outcome. The company is developing Lucid-MS, a patented, first-in-class drug candidate that approaches the disease from an entirely different angle by directly targeting the myelin sheath that MS destroys; the potential treatment is now preparing to move into phase 2 clinical trials. Quantum BioPharma stands among a group of companies pursuing therapies for neurological, autoimmune and immune-mediated conditions, a group that also includes Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and…

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

Shares of TG Therapeutics Inc (NASDAQ: TGTX) are climbing Wednesday after early-stage clinical trial data for new BRIUMVI MS formulation.

Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.

AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (profile) is determined working to change that outcome. The company is developing Lucid-MS, a patented, first-in-class drug candidate that approaches the disease from an entirely different angle by directly targeting the myelin sheath that MS destroys; the potential treatment is now preparing to move into phase 2 clinical trials. Quantum BioPharma stands among a group of companies pursuing therapies for neurological, autoimmune and immune-mediated conditions, a group that also includes Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol Myers Squibb Company (NYSE: BMY).

This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.

TG Therapeutics (TGTX) Q1 2026 Earnings Transcript

TGTX Q1 2025 Earnings Call Transcript

Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.

This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.

TG Therapeutics (TGTX) Q4 2025 Earnings Transcript

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression.

This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline.

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S.